Tesla Granted South Korean Emission Credit Trading Rights by Environmental Ministry 
Impact of Iran-Israel conflict on Stocks, Gold and Bitcoin 
Inflation is slowly falling, while student debt is climbing: 6 graphs that explain today’s CPI 
Peloton CEO Quits, Company Slashes 15% of Its Workforce as Restructuring Begins 
Ferrari Unveils New 12Cilindri Models, Bolstering Its Petrol-Powered Lineup 
Impact investing in Paris suburban ‘banlieue’ neighbourhoods 
Toyota to Accelerate Advancement of Fuel Cell Technology, Establishes Hydrogen Headquarters 
‘They don’t have enough’ – schools in England are running food banks for families 
Adidas Unveils SS24 Paris Collection for Clay Court Season 
DoorDash Faces Challenges as Shares Tumble After Earnings Forecast 
The UK has become the world’s fourth largest exporter, but can it maintain this momentum? 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Biden Administration Set to Finalize Stricter EV Tax Credit Rules 
Kroger, Disney+ Considering Partnership to Add Streaming Service to Grocery Delivery Program 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
